Exploring Novel Treatment Options for Interstitial Pulmonary Fibrosis and Progressive Pulmonary Fibrosis : Episode 17
LPA1 Modulation: Admilparant’s Role in the Evolution of IPF and PPF Therapies
Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) through myofibroblast differentiation and ECM production. Admilparant shows promising antifibrotic activity in preclinical models but requires phase 3 efficacy data. As a novel targeted therapy, it may complement existing antifibrotics, particularly for progressive phenotypes with high LPA1 expression.
Video content above is prompted by the following:
- What evidence supports the role of LPA1 in modulating fibrotic processes, particularly in IPF and PPF?
- What has the data demonstrated with admilparant so far, and what future data is needed for this therapy?
- How do you envision admilparant fitting into treatment algorithms for patients with IPF and PPF?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
